INTRODUCTION: The HIV-1 epidemic in African countries is largely due to non-B HIV-1 subtypes. Patterns and frequency of antiretroviral drug resistance mutations observed in these countries may differ from those in the developed world, where HIV-1 subtype B predominates. METHODS: HIV-1 subtype and drug resistance mutations were assayed among Nigerian patients with treatment failure on first-line therapy (plasma HIV RNA >1000 copies/mL). Sequence analysis of the reverse transcriptase and protease gene revealed drug resistance mutations and HIV-1 viral subtype. Specific patterns of mutations and clinical characteristics are described in patients with the K65R mutation. RESULTS: Since 2005, 338 patients were evaluated. The most prevalent subtypes were CRF02_AG [152 of 338 (44.9%)] and G [128 of 338 (37.9%)]. Three hundred seven of 338 (90.8%) patients had previously received stavudine and/or zidovudine + lamivudine + efavirenz or nevirapine; 41 of 338 (12.1%) had received tenofovir (TDF). The most common nucleoside reverse transcriptase inhibitor mutations observed were M184V (301, 89.1%) and K70R (91, 26.9%). The K65R mutation was present in 37 of 338 patients (10.9%). The Q151M (P < 0.05), K219R, and T69del (P < 0.01) mutations were more common in patients with K65R who had not received TDF. CONCLUSIONS: The K65R mutation is increasingly recognized and is a challenging finding among patients with non-B HIV subtypes, whether or not they have been exposed to TDF.
INTRODUCTION: The HIV-1 epidemic in African countries is largely due to non-B HIV-1 subtypes. Patterns and frequency of antiretroviral drug resistance mutations observed in these countries may differ from those in the developed world, where HIV-1 subtype B predominates. METHODS: HIV-1 subtype and drug resistance mutations were assayed among Nigerian patients with treatment failure on first-line therapy (plasma HIV RNA >1000 copies/mL). Sequence analysis of the reverse transcriptase and protease gene revealed drug resistance mutations and HIV-1 viral subtype. Specific patterns of mutations and clinical characteristics are described in patients with the K65R mutation. RESULTS: Since 2005, 338 patients were evaluated. The most prevalent subtypes were CRF02_AG [152 of 338 (44.9%)] and G [128 of 338 (37.9%)]. Three hundred seven of 338 (90.8%) patients had previously received stavudine and/or zidovudine + lamivudine + efavirenz or nevirapine; 41 of 338 (12.1%) had received tenofovir (TDF). The most common nucleoside reverse transcriptase inhibitor mutations observed were M184V (301, 89.1%) and K70R (91, 26.9%). The K65R mutation was present in 37 of 338 patients (10.9%). The Q151M (P < 0.05), K219R, and T69del (P < 0.01) mutations were more common in patients with K65R who had not received TDF. CONCLUSIONS: The K65R mutation is increasingly recognized and is a challenging finding among patients with non-B HIV subtypes, whether or not they have been exposed to TDF.
Authors: B Masquelier; E Race; C Tamalet; D Descamps; J Izopet; C Buffet-Janvresse; A Ruffault; A S Mohammed; J Cottalorda; A Schmuck; V Calvez; E Dam; H Fleury; F Brun-Vézinet Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191
Authors: José R Arribas; Federico Pulido; Rafael Delgado; Alicia Lorenzo; Pilar Miralles; Alberto Arranz; Juan J González-García; Concepción Cepeda; Rafael Hervás; José R Paño; Francisco Gaya; Antonio Carcas; María L Montes; José R Costa; José M Peña Journal: J Acquir Immune Defic Syndr Date: 2005-11-01 Impact factor: 3.731
Authors: Ravindra K Gupta; Ian L Chrystie; Siobhan O'Shea; Jane E Mullen; Ranjababu Kulasegaram; Cheuk Y W Tong Journal: AIDS Date: 2005-11-04 Impact factor: 4.177
Authors: Birgit T Røge; Terese L Katzenstein; Niels Obel; Henrik Nielsen; Ole Kirk; Court Pedersen; Lars Mathiesen; Jens Lundgren; Jan Gerstoft Journal: Antivir Ther Date: 2003-04
Authors: Victoria A Johnson; Vincent Calvez; Huldrych F Günthard; Roger Paredes; Deenan Pillay; Robert Shafer; Annemarie M Wensing; Douglas D Richman Journal: Top Antivir Med Date: 2011-11
Authors: B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki Journal: AIDS Res Hum Retroviruses Date: 2010-10-21 Impact factor: 2.205
Authors: Annemarie M Wensing; Vincent Calvez; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Huldrych F Günthard; Roger Paredes; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2019-09
Authors: Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240
Authors: Hannah O Ajoge; Michelle L Gordon; Tulio de Oliveira; Taryn N Green; Sani Ibrahim; Oladapo S Shittu; Stephen O Olonitola; Aliyu A Ahmad; Thumbi Ndung'u Journal: PLoS One Date: 2011-03-14 Impact factor: 3.240
Authors: Avelin F Aghokeng; Charles Kouanfack; Sabrina Eymard-Duvernay; Christelle Butel; Ginette E Edoul; Christian Laurent; Sinata Koulla-Shiro; Eric Delaporte; Eitel Mpoudi-Ngole; Martine Peeters Journal: J Int AIDS Soc Date: 2013-01-31 Impact factor: 5.396